Marc de Garidel, Abivax | How to make two billion 💶 exits ("smoothly") | E09

Today, I’m in Paris (🇫🇷) to chat with Marc de Garidel, the new CEO of Abivax. We talk about the challenges behind the exits and why Abivax could be a third big success. 💎 ABOUT THE SPEAKER Marc is a biopharma veteran with an impressive track record. He has made two billion-dollar exits, was CEO of Ipsen, and has recently made the biggest French IPO ever with Abivax. He has also raised $60M series B for Massachusetts-based Corvidia Therapeutics before being acquired for $2.1B by Novo Nordisk. He also was the CEO of CinCor Pharma which sold for $1.8B to AstraZeneca in 2023. I’ve never met Marc but I heard many great things about him. 📜 TRANSCRIPT Read the full transcript here: https://flot.bio/episode/marc-de-garidel-abivax-exit/ 🫶 FOLLOW US Newsletter: http://eepurl.com/h_fnmH LinkedIn: https://www.linkedin.com/company/flot-bio/ X (Twitter): https://x.com/FlotBio 🎙️ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 10k monthly views. Free. ⭐️ SPONSORSHIP Wanna reach 10,000+ biotech leaders at companies like BioNTech, Immunocore or Genmab? Feel free to message Nick ([email protected]) to learn more. 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. ⏰ TIMESTAMPS [00:00:00] Intro [00:01:32] Behind the scene of the 2 billion-dollar exits [00:20:48] Lessons on compliance analysis [00:24:09] What to do when the market is against you [00:36:08] Abivax: Phase II compared to standard of care [00:42:51] IBD and the microbiome [00:51:20] Why is 70% of the market in the US? [00:59:07] The best way to sell a company is to make a great product [01:03:48] Find people who inspire you [01:10:45] Thanks for listening 🙏